Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Intensity Therapeutics, Inc. Common stock (INTS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: INTS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -60.26% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 35.12M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 31811 | Beta - | 52 Weeks Range 1.50 - 5.28 | Updated Date 03/30/2025 |
52 Weeks Range 1.50 - 5.28 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.07 |
Earnings Date
Report Date 2025-03-14 | When - | Estimate - | Actual -0.2175 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -94.96% | Return on Equity (TTM) -173.99% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 27150842 | Price to Sales(TTM) - |
Enterprise Value 27150842 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -4.72 | Shares Outstanding 15104800 | Shares Floating 5084730 |
Shares Outstanding 15104800 | Shares Floating 5084730 | ||
Percent Insiders 43 | Percent Institutions 18.01 |
Analyst Ratings
Rating 4.5 | Target Price 10 | Buy 2 | Strong Buy 2 |
Buy 2 | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Intensity Therapeutics, Inc. Common stock
Company Overview
History and Background
Intensity Therapeutics, Inc., founded in 2012, is a clinical-stage biotechnology company focused on developing proprietary cancer therapeutics that target solid tumors. They utilize a patented DfuseRxSM technology platform to enhance drug delivery and efficacy.
Core Business Areas
- Drug Development: Focuses on the research, development, and clinical testing of novel cancer therapies using the DfuseRxSM technology platform. Their lead product candidate is INT230-6.
Leadership and Structure
Lewis H. Bender serves as the Chief Executive Officer and President. The company has a board of directors and a management team overseeing research, clinical development, and business operations.
Top Products and Market Share
Key Offerings
- INT230-6: INT230-6 is Intensity Therapeutics' lead product candidate. It's a product designed for direct intratumoral injection, aiming to deliver chemotherapy drugs directly into solid tumors while also eliciting an immune response. Currently in clinical trials. Market share N/A as it is still in development and has not been commercialized. Competitors for INT230-6 include other companies developing intratumoral cancer therapies and standard systemic chemotherapies.
Market Dynamics
Industry Overview
The oncology market is a large and growing market, driven by an aging population, increasing prevalence of cancer, and advances in treatment options. Significant unmet needs remain, particularly for patients with solid tumors who have failed standard therapies.
Positioning
Intensity Therapeutics is positioned within the oncology market as a company developing novel intratumoral cancer therapies. Their DfuseRxSM technology is intended to provide a competitive advantage by enhancing drug delivery and stimulating an immune response.
Total Addressable Market (TAM)
The global solid tumor market is estimated to be in the hundreds of billions of dollars. Intensity Therapeutics is positioned to capture a portion of this market with successful clinical development and commercialization of INT230-6.
Upturn SWOT Analysis
Strengths
- Proprietary DfuseRxSM technology platform
- INT230-6 showing promising early clinical results
- Experienced management team
- Targeting a large and unmet medical need
Weaknesses
- Limited financial resources
- Dependence on the success of INT230-6
- High risk associated with drug development
- No currently marketed products
Opportunities
- Positive clinical trial results for INT230-6
- Partnerships with larger pharmaceutical companies
- Expansion of DfuseRxSM platform to other cancer types
- Acquisition by a larger pharmaceutical company
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other cancer therapies
- Economic downturn impacting funding for biotechnology companies
Competitors and Market Share
Key Competitors
- ONCR
- MRTX
- NKTR
Competitive Landscape
Intensity Therapeutics competes with other biotechnology companies developing cancer therapies, including both intratumoral and systemic approaches. Its competitive advantage lies in its DfuseRxSM technology.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily defined by the advancement of INT230-6 through clinical trials.
Future Projections: Future growth is dependent on positive clinical trial outcomes and potential regulatory approvals. Analyst estimates are speculative and contingent on clinical success.
Recent Initiatives: Focus on advancing the Phase 1/2 clinical trial of INT230-6 and exploring potential partnerships.
Summary
Intensity Therapeutics is a clinical-stage biotechnology company focused on a novel approach to cancer treatment. Its success hinges on the outcome of clinical trials for its lead product candidate, INT230-6. While its DfuseRxSM technology provides a unique platform, the company faces significant risks associated with drug development and limited financial resources. Securing partnerships and achieving positive clinical results are crucial for future growth.
Similar Companies
- ONCR
- MRTX
- NKTR
- AGEN
Sources and Disclaimers
Data Sources:
- Intensity Therapeutics Investor Relations
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment decisions should be made based on individual research and consultation with a qualified financial advisor. Market Share data is based on revenue size relative to overall Oncology Market Size. The data on this specific company is limited, because it is a very new company and is very small.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Intensity Therapeutics, Inc. Common stock
Exchange NASDAQ | Headquaters Shelton, CT, United States | ||
IPO Launch date 2023-06-30 | Founder, President, CEO & Chairman of the Board Mr. Lewis H. Bender M.A., M.B.A., M.S. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5 | |
Full time employees 5 | |||
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs in the United States. Its lead product candidate includes INT230-6, which is in human clinical studies for the treatment of refractory solid tumors, such as soft tissue sarcoma which is in phase 3 trails; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.